Abstract: The invention provides an antibody that specifically binds to a 5? to 3? exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5? to 3? exonuclease activity of a DNA polymerase, or a fragment thereof.

Abstract: To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.

Abstract: Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R1, R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.

Abstract: The invention provides an antibody that specifically binds to a 5? to 3? exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5? to 3? exonuclease activity of a DNA polymerase, or a fragment thereof.

Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.

Abstract: A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an ?-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the ?-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.

Abstract: Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R1, R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.

Abstract: A method for enabling rapid and accurate determination of the number of bacterial cells in a specimen using a PCR method includes the following steps: (1) a first PCR step of carrying out a PCR method using a nucleic acid derived from a specimen as a template and a universal primer pair for amplifying a bacterial 16S rRNA gene to obtain a first amplification product; (2) a second PCR step of carrying out a nested PCR method using a primer pair(s) for amplifying an internal sequence(s) of the sequence of the first amplification product obtained by the first PCR step to obtain a second amplification product; and (3) a bacterial number determination step of obtaining the number of bacterial cells in the specimen based on the amount of the second amplification product obtained in the second PCR step and using calibration data.

Abstract: A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an ?-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the ?-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.

Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.

Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.

Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.

Abstract: The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.

Abstract: A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell.

Abstract: A magnesium alloy is provided that includes: 5.0 mass % or more and 15.0 mass % or less of Al; 2.5 mass % or more and 7.0 mass % or less of Sr; 0.05 mass % or more and less than 3.0 mass % of Ca; and 0.1 mass % or more and 0.6 mass % or less of Mn, with a remainder including Mg and inevitable impurities.

Abstract: A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell.

Abstract: An Al—Mg—Si-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg2Si is crystallized in a fine agglomerate form.

Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.

Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.